Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olgotrelvir - Sorrento Therapeutics

Next Previous
Drug Profile

Olgotrelvir - Sorrento Therapeutics

Alternative Names: OVYDSO; OVYDSO - Sorrento Therapeutics; STI-1558

Latest Information Update: 27 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Texas A&M University
  • Developer ACEA Therapeutics
  • Class Antivirals; Small molecules
  • Mechanism of Action Cathepsin L inhibitors; Coronavirus 3C-like proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 13 Jun 2024 Efficacy and adverse events data from a phase III trial in COVID-2019 infections presented at the ASM Microbe 2024 (ASM-2024)
  • 09 Nov 2023 Zhejiang ACEA Pharmaceutical completes a phase I trial in COVID-2019 infections (In volunteers) in China (PO) (NCT05754411)
  • 08 Nov 2023 Zhejiang ACEA Pharmaceutical completes a phase I bioequivalence trial (In volunteers) in China (PO) (NCT06044233)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top